LL-37-Derived Antimicrobial Peptides Against Resistant Biofilms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bacterial populations develop resistance to antimicrobial peptides, particularly those derived from LL-37, such as WLBU2, posing challenges in treating antibiotic-resistant infections, especially in biofilms and strains like P. aeruginosa.
Innovation Solution
Administering formulations containing antimicrobial peptides or their salts with specific sequences and therapeutic amounts to target mutations in the pmrABC operon and other genes, inhibiting bacterial growth and reducing resistance development, even in multiple-drug-resistant bacteria and biofilms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antimicrobial peptides derived from LL-37 (such as WLBU2) are used to treat bacterial infections, then high antimicrobial activity against ESKAPE pathogens is achieved, but resistance development occurs particularly in P. aeruginosa
Solution Approach 1:
The patent modifies the amino acid sequence of LL-37-derived peptides to create variants with altered properties. Specifically, mutations are introduced to reduce binding affinity to human proteins (like heme and hemoglobin) while maintaining or enhancing antimicrobial activity, thereby preventing resistance development in P. aeruginosa and other ESKAPE pathogens
Solution Approach 2:
The invention creates composite antimicrobial formulations by combining modified LL-37 peptide variants with other antimicrobial agents or adjuvants. This multi-component approach synergistically enhances antimicrobial efficacy while reducing the selective pressure that drives resistance development in bacterial populations
2Reliability
If polymyxin peptides are used as antimicrobial agents, then treatment of gram-negative bacteria is achieved, but toxicity and resistance development are significant problems
Solution Approach 1:
The patent fundamentally changes the chemical structure and properties of traditional polymyxin peptides by using LL-37-derived sequences. These modified peptides maintain cationic charge for membrane binding but have reduced affinity for human cell membranes and proteins, thereby reducing toxicity while preserving antimicrobial efficacy against gram-negative bacteria
Solution Approach 2:
The modified LL-37 peptides act as intermediaries that bridge the gap between traditional polymyxin activity and reduced toxicity. They maintain the ability to bind and disrupt bacterial membranes while having reduced affinity for human heme, hemoglobin, and cell membranes, thus serving as a safer alternative to polymyxins
3Ease of operation
If antimicrobial peptides are tested against planktonic cells, then antibiotic activity is easily measured, but biofilms exhibit high antibiotic tolerance
Solution Approach 1:
The patent modifies peptide properties such as amphipathicity, charge distribution, and hydrophobicity to enhance penetration through biofilm matrices. The modified LL-37 variants have improved ability to disrupt biofilm structure and penetrate into biofilm-associated bacteria, overcoming the tolerance that protects planktonic cells
Solution Approach 2:
The invention creates antimicrobial peptides with dynamic properties that allow them to adapt their mode of action. The modified peptides can interact with both planktonic and biofilm-associated bacteria through multiple mechanisms, including membrane disruption, intracellular target binding, and biofilm matrix degradation, making them effective against both growth states
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces bacterial levels and inhibits resistance development, treating infections in various strains, including A. baumannii and P. aeruginosa, even in the presence of biofilms and multiple drug resistances.
Implementation Method 1
WLBU2 (also called PLG0206) is an example of an engineered peptide, derived from and inspired by the LL-37 peptide produced by our own bodies, which inserts into the bacterial membrane and leads to cell death
Data Source
AI summary
Provided in this disclosure are methods of treating a bacterial infection comprising administering a formulation comprising an antimicrobial peptide described herein when administered to a subject. Further provided herein are methods of treating a bacterial infection wherein the bacterial infection comprises a bacterium with a mutation in a gene resulting in antibiotic resistance.